(Q50571267)

15 March 2018

title

Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. (English)

1 reference

15 March 2018

1 reference

Henry L Y Chan

1

1 reference

15 March 2018

Hong Ren

2

1 reference

15 March 2018

Wan C Chow

3

1 reference

15 March 2018

Theodore Wee

4

1 reference

15 March 2018

Interferon beta-1a Hepatitis C Study Group

5

1 reference

15 March 2018

language of work or name

English

0 references

publication date

1 August 2007

1 reference

15 March 2018

published in

Hepatology

1 reference

15 March 2018

volume

46

1 reference

15 March 2018

issue

2

1 reference

15 March 2018

page(s)

315-323

1 reference

15 March 2018

Approach to the patient with chronic hepatitis C virus infection

cites work

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway

21 January 2018

1 reference

Chronic hepatitis C virus management: 2000-2005 update

21 January 2018

1 reference

Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C

21 January 2018

1 reference

Is interferon-beta an alternative treatment for chronic hepatitis C?

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

7 January 2021

American Gastroenterological Association medical position statement on the management of hepatitis C

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

1 reference

7 January 2021

Structure of the human interferon alpha receptor.

1 reference

7 January 2021

The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study

1 reference

7 January 2021

High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group.

1 reference

7 January 2021

A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C.

1 reference

7 January 2021

A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta

1 reference

7 January 2021

Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C

1 reference

7 January 2021

Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen

1 reference

7 January 2021

Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C.

1 reference

7 January 2021

Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators

1 reference

7 January 2021

Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients

1 reference

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

7 January 2021

Diagnosis, management, and treatment of hepatitis C

1 reference

7 January 2021

The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1.

1 reference

7 January 2021

Treating viral hepatitis C: efficacy, side effects, and complications

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21683

1 reference

15 March 2018

PubMed ID

17654600

1 reference

15 March 2018